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During the 171st European Neuromuscular Centre
international workshop Standards of care and manage-
ment of facioscapulohumeral muscular dystrophy (FSHD)
in January 2010 [1], it was concluded that there was a need
for further discussion to better deﬁne the “gold standard”
for diagnostic procedures for FSHD. With the increasing
complexity of the genetics of FSHD, it is important to
reach an international consensus on the molecular testing
methods. To this end, a meeting was held with 39 scientists
from around the world at the Leiden University Medical
Center on June 9, 2010 to establish consensus Best Practice
Guidelines on Genetic Diagnosis of FSHD.2. The clinical perspective
FSHD is a myopathy with a descending order of muscle
involvement. As facial weakness often goes unnoticed, the
most frequent presenting symptom involves scapular ﬁxa-
tor weakness. In the occasional event that foot extensor
or pelvic girdle weakness are the ﬁrst signs noticed by an
FSHD patient, the doctor always ﬁnds facial or shoulder0960-8966  2011 Elsevier B.V.
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Open access under the Elsevier OA license.weakness as well [2]. When a physician concludes a facio-
scapulohumeral syndrome, the odds are in favor of FSHD
and genetic testing is the preferred diagnostic choice. Some
physicians include CK measurement as a check to justify
the waiting period for DNA results. DNA is studied for
conﬁrmation (Table 1) if a physician considers FSHD as
a high probability. If he wants to exclude non-penetrance
in a sib older than 18 years, he might want genetic testing
for exclusion.3. General description of the genetics of FSHD
FSHD is an autosomal dominant disorder that in the
large majority of patients (>95%; FSHD1) is caused by a
contraction of the polymorphic macrosatellite repeat
D4Z4 on chromosome 4q35. The D4Z4 repeat array con-
sists of repeat units that are 3.3 kb in size and which are
ordered head to tail. The size of the D4Z4 repeat array
ranges in size between 11 and 100 units in control individ-
uals. In patients with FSHD1 the D4Z4 repeat array is con-
tracted to a size between 1 and 10 units. In general, repeat
array sizes between 1 and 3 units are associated with an
earlier onset and more progressive and severe phenotype
than arrays with >3 units. The contraction of the D4Z4
repeat array coincides with a loss of repressive chromatin
markers and reduced DNA CpG methylation levels at
D4Z4 [3].
Based on sequence variations in and around the D4Z4
repeat, at least 17 genetic variants of 4q35 have been iden-
Table 1
Flowchart for neurologist for conﬁrmation or exclusion of FSHD by
genetic analysis. For the conﬁrmation of FSHD additional of muscle
biopsy studies should be considered when the standard FSHD analysis is
negative. In these cases other test to conﬁrm the D4Z4 contractions are
recommended (see Fig. 3).
Clinical certainty D4Z4 contraction on 4q
Confirmation STOP EMG Rule in:
FSHD Biopsy p13E-11 deletion
other myopathy Short 4q hybrid
FSHD2
(See Figure 3)
Exclusion Rule out:
FSHD Short 10q
Short 4qB
Short translocated 4q
(See Figure 3)
No D4Z4 contraction
STOP
a
b
c
Fig. 1. (a) FSHD is caused by a contraction of the D4Z4 repeat array on
chromosome 4qA to a size between 1 and 10 repeat units. The D4Z4
repeat array in controls ranges between 10 and 100 units. An almost
identical and equally polumorphic D4Z4 repeat array can also be found
on chromosomes 4qB and 10q, but contraction on these chromosomes do
not result in FSHD. (b) Southern blot discrimination between the D4Z4
homologs is based on a speciﬁc hybridization probes distal to D4Z4 (4qA/
4qB) and on the restriction enzymes BlnI and Xap which speciﬁcally digest
repeat units from 10q and 4q, respectively. (c) Representation of typical
Southern blot analysis of D4Z4 repeats using pulsed ﬁeld gel electropho-
resis (PFGE). Genomic DNA is double digested with EcoRI and HindIII
(E), EcoRI and BlnI (B), or digested with XapI, and, after PFGE and
464 R.J.L.F. Lemmers et al. / Neuromuscular Disorders 22 (2012) 463–470tiﬁed that can be roughly be separated in the subgroups
4qA and 4qB (Fig. 1a) [4]. In addition, a polymorphic
repeat array highly homologous to the D4Z4 repeat array
can also be found on chromosome 10q (Fig. 1a) [5]. How-
ever, only D4Z4 contractions on chromosome 4qA have
been reported to be associated with FSHD with the excep-
tion of a recently published case with complex D4Z4 rear-
rangement of chromosome 10 [6,7]. Recently it has been
shown that speciﬁc sequence variations between 4qA,
10qA and 4qB chromosomes in the region distal to D4Z4
contribute to the permissiveness of the 4qA variant [7].
Thus repeat arrays <10 units on chromosomes 4qB and
10q can be frequently encountered in the normal popula-
tion without apparent pathogenic consequences [8]. Yet,
the occurrence of D4Z4 repeat array contractions on
non-permissive chromosomes hampers the genetic analysis
of FSHD.
In addition to the speciﬁcity for the genetic background
to the development of FSHD also other types of rearrange-
ments of the D4Z4 locus can complicate the diagnosis of
FSHD. This includes for example gonasomal mosaicism
for the D4Z4 contraction [9], or cases in which the con-
tracted D4Z4 repeat may go unnoticed due to deletion of
the diagnostic probe region [10]. Finally an epigenetic var-
iant of FSHD has been identiﬁed (FSHD2); this variant
shows similar clinical features and changes of the chroma-
tin structure of D4Z4 in the absence of contraction [11].blotting, hybridized with probe p13E-11. The E lane typically displays
four alleles, two from chromosome 4 (grey lines) and two from
chromosome 10 (black lines). The B lane only reveals the D4Z4 repeats
from chromosome 4, the X lane those from chromosome 10. The left
genotype displays a short 4-type D4Z4 repeat and is from an FSHD
patient. The right genotype has a short 10-type D4Z4 repeat and is derived
from an unaﬀected individual.4. Diagnostic techniques
Several diagnostic methods to perform the molecular
diagnosis for FSHD have been developed and all are based
on the determination of the length of the D4Z4 repeat
array. The most common method is by Southern blotting
of genomic DNA after digestion with a speciﬁc set of
restriction enzymes, but some labs also use a long range
PCR method [12] to size the D4Z4 repeat array. Currently,
molecular combing is in development, based on ﬂuores-
cence in situ hybridization (FISH) of stretched DNA mol-
ecules [13]. All three techniques use genomic DNA isolated
from peripheral blood lymphocytes (PBLs), chorionicvillus sampling or cultured amniotic ﬂuid cells, but the
DNA isolation method can be diﬀerent.
For the isolation of PBL from peripheral blood, the ini-
tial erythrocyte lysis protocol is comparable between the
diﬀerent techniques, but the handling of the white blood
cell (WBC) pellets can be diﬀerent. Liquid DNA can be iso-
lated from the WBC pellet either manually [14] or in an
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and long range PCR. However, the mechanical stress dur-
ing the preparation of liquid DNA generally leaves geno-
mic DNA fragments <200 kb and further shearing during
the handling of the DNA might result in even smaller frag-
ments. Therefore liquid DNA is generally not suitable to
size D4Z4 repeat arrays >50 kb and as a consequence not
all D4Z4 arrays from 4q and 10q in an individual will be
visualized. Furthermore, the identiﬁcation of all D4Z4
fragments in a single individual may assist in the identiﬁca-
tion of complex D4Z4 rearrangements like gonasomal
mosaicism and D4S104F1 deletions as will be explained
in the next paragraph. Ideally the analysis of the D4Z4
repeat arrays is performed on agarose embedded DNA
plugs in which high molecular weight DNA can be pre-
served enabling the identiﬁcation of all four D4Z4 repeats
by Southern blotting (http://www.urmc.rochester.edu/
ﬁelds-center/). These agarose plugs are also required for
the FSHD diagnosis by molecular combing.
5. Southern blotting
The most common method to perform the molecular
diagnosis for FSHD is by Southern blotting. For this
method high molecular weight genomic DNA in plugs or
dissolved in Tris buﬀer is digested with restriction enzymes
(in general with EcoRI or with EcoRI andHindIII) that cut
at both ends of D4Z4 repeat array, thereby releasing com-
plete D4Z4 repeat arrays with little ﬂanking sequences. For
this reaction approximately 5 lg of liquid genomic DNA is
required or alternatively 500,000 cells (approximately
3.5 lg DNA). Subsequently, size separation of the digested
DNA is performed by linear gel electrophoresis (LGE) or
by pulsed ﬁeld gel electrophoresis (PFGE). LGE allows
the sizing of DNA fragments between 3 and 50 kb which
enables the identiﬁcation of FSHD-sized fragments. How-
ever, PFGE together with agarose embedded DNA plugs
allows separation of fragments up to hundreds of kilobases
and therefore enables the identiﬁcation of all four alleles
(chromosomes 4 and 10) [15].
After separation the DNA is transferred to a Nylon
membrane by Southern blotting and then the D4Z4 repeat
arrays are visualized using probe p13E-11. Probe p13E-11
recognizes the region immediately proximal to D4Z4 con-
tained within the EcoRI fragment and is a suitable probe
for most cases. Southern blot hybridizations are often per-
formed with radioactive labeled probes using the isotope
phosphorus 32 (32P) with has a half-life of 14 days. How-
ever, all the major diagnostic probes currently available
can also be labeled using non-radioactive techniques which
do not need a special designated area or laboratory for per-
forming the analysis and is much more stable (up to 1 year)
than radioactive probes making it more suitable for smaller
diagnostic centers [16].
The detection of chromosome 4-speciﬁc D4Z4 repeat
arrays is complicated by the presence of an equally poly-
morphic D4Z4-like repeat array on chromosome 10q. Ingeneral, D4Z4 sequences on chromosome 4q and 10q are
about 99% identical. To discriminate between permissive
4q and non-permissive 10q chromosomes the Southern blot
method takes advantage of consistent sequence variations
between both repeat arrays which create diﬀerent restric-
tion enzyme recognition sites between 4q and 10q. In two
separate reactions a discriminative digestion for chromo-
some 4 and 10 type D4Z4 repeat arrays is performed. Dou-
ble digestion with restriction enzymes EcoRI and BlnI
leaves chromosome 4-type D4Z4 units undigested while
fragmenting chromosome 10-type units [17]. The restriction
enzyme XapI does the opposite [18]. Fig. 1b illustrates how
these restriction enzymes enable the discrimination
between contracted D4Z4 repeat arrays from chromo-
somes 4 and 10. Consequently, the Southern blot-based
diagnostic method for FSHD is a very informative method
that enables the accurate sizing and chromosomal speciﬁc-
ity of the D4Z4 fragments (Fig. 1c). On the other hand this
method is very laborious and it requires large amounts (at
least 15 lg) of high molecular weight genomic DNA. Fur-
thermore, the whole procedure takes more then a week
from peripheral blood withdrawal until the D4Z4 frag-
ments are visualized by Southern blotting, hybridization
and image exposure. The use of non-radioactive labeling
can dramatically reduce the time that analysis takes due
to short exposure time. In addition, the recently developed
molecular combing technology may also provide a less
labor-intensive alternative [13]. Finally, in a substantial
number of cases complex D4Z4 repeat arrays can cause
problems in interpretation or even diagnostic errors.
6. Identiﬁcation of complex D4Z4 rearrangements by
Southern blotting: complicating D4Z4 rearrangements
The ancestral D4Z4 repeat arrays on chromosome 4q
(D4Z4 units are XapI sensitive and BlnI resistant) and its
homologue on chromosome 10q (D4Z4 units are BlnI sen-
sitive and XapI resistant) have been involved in several
complex rearrangements, which resulted in hybrid repeat
arrays consisting of 4q- and 10q-like repeat units on both
chromosomes. About 6% of the European chromosomes
4 (12% of the individuals) carry hybrid repeat arrays and
repeat contractions in hybrid D4Z4 arrays below 11 units
have been shown to be pathogenic (Fig. 2a). After this
duplication, the hybrid D4Z4 repeat array on chromosome
10q likely homogenized into an array with only 10-type
D4Z4 units. In addition homogeneous 4 type repeat arrays
have been translocated to chromosome 10q. About 8% of
the European chromosome 10 belong to this ancient trans-
location group (16% of the European individuals) [4]. Like
the common chromosome 10q, D4Z4 contractions on these
10q translocation chromosomes are non-pathogenic
(Fig. 2b).
As shown in Fig. 2a and b these complicated situations
can be identiﬁed using PFGE and EcoRI/BlnI and XapI
digestions. In total these remnants of D4Z4 evolution give
rise to complex D4Z4 proﬁles in almost 30% of the
a b c
d e
Fig. 2. (a) Representation of a Southern blot result of an FSHD patient carrying a short hybrid repeat array on chromosome 4, which consist of both 4-
type and 10-type D4Z4 units. The ﬁrst few units of this hybrid array are 10-type and as a consequence the fragment is not visible in lane B (EcoRI and BlnI
double digestion). However, the XapI digestion does not show a typical 10q pattern as the corresponding fragment is not visible at the expected size in lane
X, like the two larger 10q fragments in the same individual (grey fragments). This complex genotype can be elucidated by the XapI digestion. Normal-sized
hybrid repeat arrays can be found in about 10% of the control population and therefore the prevalence of a short hybrid FSHD repeat array might also be
about 10%. (b) Southern blot representing a control individual carrying a short 4-type D4Z4 repeat on chromosome 10. Typical these translocated repeat
array on chromosome 10 consist of a homogeneous 4-type (BlnI-resistant, XapI-sensitive) repeat array and is diﬃcult to distinguish from standard
chromosome 4 repeat arrays. However, contractions of these repeats do not cause FSHD. Normal-sized hybrid repeat arrays can be found in about 10% of
the control population and in less than 1% of these cases the translocated repeat array is shorter than 40 kb. On a PFGE gel the presence of a translocated
repeat array is clearly visible by the appearance of three 4-type fragments. Translocated repeats on 10q can end with the distal A or B variation. By
performing a SSLP analysis this genotype can be recognized as translocated 4A-type repeats on chromosome 10 have unique SSLP fragments of 176 or
180 bp. Thus this complex genotype can be elucidated by PFGE and SSLP analysis.
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ought to attain more attention in the assignment of the
repeats to the appropriate chromosome by Southern
blotting because the discriminating restriction enzymes
typically used in the diagnosis are not informative. A recent
population study shows that about 40% of the African
individuals carry a hybrid repeat arrays on chromosome
4q [4].
Based on a large polymorphism involving a beta-satellite
repeat immediately distal to the D4Z4 repeat, two variants
of chromosome 4q have been detected; 4qA and 4qB, and a
study in several families shows that contracted D4Z4
repeat arrays on 4qB chromosomes do not cause FSHD
[8]. As non-pathogenic short D4Z4 repeat arrays on 4qB
chromosomes can be detected in about 1% of the European
controls they might hamper the genetic analysis for FSHD
in some cases (Fig. 2c). The recognition of 4qA- and 4qB-
type chromosomes requires the use of speciﬁc probes
(probe A and B) for which the chromosomal DNA hasto be digested with another restriction enzyme (HindIII)
[6]. Subsequent steps are similar as for the D4Z4-sizing
experiment with p13E-11.
About 10–30% of FSHD patients are diagnosed with a
new D4Z4 repeat contraction event. These new mutations
can occur either in the germ-line or by a postzygotic rear-
rangement resulting in gonasomal mosaicism [20]. As
shown in Fig. 2d, mosaicism for the D4Z4 contraction is
unmistakable detected when performing PFGE on DNA
agarose plugs by the presence of an additional D4Z4 frag-
ment. Three fragments show a normal intensity (are present
in all cells), while the two more faint bands represent the
repeat array size in the two mosaic cell populations. Previ-
ous studies have shown that, while the contraction can be
identiﬁed by LGE, in virtually all cases the mosaic nature
of the contraction is not recognized by this technique [9].
Even if liquid DNA is used in a PFGE setting the mosaicism
is often not recognized as not all D4Z4 alleles are visualized
due to shearing of the repeat arrays larger than 100 kb.
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blood is often similar to that in muscle and probably also
to that in germ line tissue [21]. Therefore, it is important
that the mosaic nature of the contraction is recognized as
this might have important clinical consequences and conse-
quences for genetic counseling. Firstly, the disease in a
mosaic individual is often much milder as only part of
the muscle cells carry the mutation and consequently the
oﬀspring that inherits the genetic lesion is generally more
severely aﬀected than the mosaic parent. Secondly, the risk
of transmitting the disease is smaller in mosaic FSHD
patients as their germ-line is (likely) also mosaic [9].
In some patients the short D4Z4 repeat array remains
invisible as the genetic lesion is not restricted to the
D4Z4 repeat, but extends proximally and can include the
D4F104S1 region that is recognized by probe p13E-11.
Similar to D4Z4 mosaicism, genotypes that carry a p13E-
11 deletion on one of their chromosomes can be easily
detected by using PFGE on high quality DNA because in
these cases the genotype only reveals three D4Z4 associated
repeat arrays (Fig. 2e). Using LGE, these situations can not
be distinguished from a control genotype and are often
misinterpreted. Previously, these deletions were estimated
to occur in approximately 3% of all the FSHD patients
[10]. These proximally extended deletions can be identiﬁed
by re-probing of the membrane by stringent hybridization
conditions with probe D4Z4, which will visualize the
missed D4Z4 fragment, or probes 4qA and 4qB [22].
Recently, an epigenetic variant of FSHD has been iden-
tiﬁed (FSHD2) that is not associated with repeat contrac-
tions [11]. This variant is clinically indistinguishable from
contraction-dependent FSHD1 and can explain about 3%
of the FSHD patients [23]. FSHD2 requires a permissive
4qA chromosome like FSHD1, but the loss of repressive
chromatin marks and CpG hypomethylation at D4Z4 is
more profound in this variant and can also be found on
the D4Z4 arrays from the homologous chromosome 4q
and both chromosomes 10q. Unfortunately, detection of
FSHD2 is still in the research phase and is not carried
out in a diagnostic setting.
7. Other diagnostic methods
As shown in the previous paragraphs, the standard
Southern blotting diagnostic methods enable the identiﬁca-
tion of FSHD1 in about 95% of the cases. Some complicat-
ing genetic situations might result in false positive or false
negative testing and therefore additional analysis Southern
blot-based methods have been developed that increased the
sensitivity and speciﬁcity. However, these methods are
expensive, labor intensive and it requires large amounts
of high molecular weight DNA. As currently the diagnostic
tests for most diseases are optimized for high throughput
sample handling there is clearly a need for an improved
method to perform the molecular diagnosis for FSHD1.
Therefore other methods have been introduced, which will
be discussed in the following paragraphs.7.1. Long range PCR
D4Z4 sizing can be performed by long range (LR-)
PCR. LR-PCR uses speciﬁc primers that are designed
proximally and distally to the D4Z4 repeat array. The
PCR program takes about 13 h and the size of the D4Z4
array is visualized directly after LGE. This method enables
repeat array sizing in as little as 400 ng of genomic DNA
and ideally can be performed within one day [12]. How-
ever, the method does not allow the identiﬁcation of repeat
arrays that are >6 repeat units. In Japan the pathogenic
D4Z4 repeat in patients ranges between 1 and 7 units and
therefore LR-PCR allows the detection of 95% of the cases.
However, in European FSHD patients the pathogenic
D4Z4 repeat ranges between 1 and 10 units. Repeat array
sizes between 6 and 10 units are common in most European
familial cases. Therefore, the LR-PCR method can not be
advised for the identiﬁcation of FSHD in most European
FSHD families. Another concern for this method is that
in case of a negative PCR result it is unclear if either the
DNA available was unsuitable for PCR ampliﬁcation due
to protein and salt impurities or due to low DNA quality
or that the individual does not carry a contracted D4Z4
repeat array.
7.2. Molecular combing
Currently, a method based on Molecular Combing
(MC) is in development that may provide a good alterna-
tive for the molecular diagnosis of FSHD [13]. By this
method high quality genomic DNA from an agarose plug
is stretched on a cover slip after which the D4Z4 fragments
are visualized and sized with ﬂuorescence labeled probes
using ﬂuorescence microscopy. Speciﬁc probes have been
designed to recognize the region proximal to D4Z4 in a
speciﬁc pattern to discriminate between chromosomes 4
and 10. In addition, probes with diﬀerent ﬂuorescence
labels have been developed that recognize the p13E-11
region, D4Z4 and that discriminate between the distal A
and B in the region distal to D4Z4. As the chromosome
4 and 10 discrimination for this technique is based on a
large region proximal to D4Z4 rather than on partially spe-
ciﬁc restriction enzymes within D4Z4, this method over-
comes many of the previously mentioned complicating
factors including hybrid arrays, translocated repeat arrays
and proximally extended deletions. MC for FSHD is not
yet widely operational and requires dedicated personnel
but might prove to be a promising new development in
the diagnostic toolkit for FSHD if the D4Z4 repeat array
sizing proofs to be accurate and when the microscopic
analysis becomes completely automated.
7.3. Marker analysis
Another method that might assist in the molecular diag-
nosis for FSHD is based on DNA markers proximal to
D4Z4. By using this method it is not possible to determine
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the segregation of a pathogenic chromosome after preced-
ing detailed chromosomal analysis including D4Z4 sizing
of other family members. This method has mainly been
setup as a rapid screening to determine the chromosome
4 haplotype, for prenatal diagnosis and for preimplanta-
tion genetic diagnosis (PGD). Until now, several polymor-
phic markers proximal to D4Z4 at chromosome 4q35 have
been tested for PGD but most of them are localized at a
large distance from the D4Z4 repeat (0.55–1.88 Mb). In a
multiplex PCR-based approach several markers were com-
bined and technically fulﬁll guidelines for single-cell analy-
sis. However, a relatively high recombination risk was
shown for these large distance markers which hamper its
application to PGD, as well as the absence of suitable
markers distal to the repeat [24]. More recently, polymor-
phic DNA markers have been described that are only a
few kb proximal to the D4Z4 repeat (SSLP and p13E-11
region) [4,25]. The SSLP marker is low polymorphic and
is in linkage disequilibrium with the sequence variation in
p13E-11. It has been shown that pathogenic contractions
are associated with the most common chromosome 4qA
variant 4A161 and the rare variants 4A159, 4A168 and
hybrid 4qA chromosomes. Both markers have been tested
for there utility as a predictive marker for segregation stud-
ies of the pathogenic FSHD chromosome. The most recent
study suggests that the SNPs in the p13E-11 are informa-
tive and can be used in most cases. These results are based
on the detection of the sequence variations that are associ-
ated with the 4A161 chromosome [26]. However, permis-
sive rare variants of chromosome 4qA will be missed in
the analysis as they are associated with non-4A161 varia-
tions. Furthermore, for both markers the procedure recog-
nizes both chromosomes 4 and 10 and one non-permissive
chromosome 10 variant is also associated with the 4A161
SNPs. In addition, the 4A161 chromosome is the most
common 4qA variant and more than 50% of the European
population is carrier of this chromosome. Therefore, the
speciﬁcity of the test in a familial segregation study is low
as often one of the parents is carrier of a 4A161 chromo-
some with a normal-sized D4Z4 repeat array. On the other
hand the SSLP analysis can be useful for preventing false
positive testing in case of short translocated 4qA repeat
on chromosome 10q (SSLP analysis will identify a 176 or
a 180 peak corresponding to a 10A176 or a 10A180T chro-
mosome, respectively) (Figs. 2b and 3).
8. Types of Laboratory referral and their analysis
In diagnostic testing for FSHD, particularly if based on
p13E-11 LGE analysis alone, there is potential for a false
negative or a false positive result. A false negative result
would occur where the true FSHD patient has a proxi-
mal-extending D4Z4 deletion which also deletes the
p13E-11 probe region (D4F104S1 locus); or where the
patient has a shortened but hybrid D4Z4 array at 4q35
containing 10-type repeats. There are also patients withFSHD2 who are clinically indistinguishable from FSHD1
but who do not have a D4Z4 contraction at 4q35, and
whose diagnosis would currently rest on their clinical
presentation.
A false positive result would occur where a patient who
does not have FSHD, has a shortened D4Z4 fragment,
either as the chromosome 10q26 homologous repeat array,
or at 4q35 but linked with a non-permissive 4qB or SSLP
marker haplotype.
In order to minimize false negatives and false positives,
and to appropriately target further testing, all participants
at the Best Practice Meeting agreed that it would be very
helpful to know at the time of referral of DNA to the
lab, what the clinician’s expectation would be for the like-
lihood of the patient having true FSHD. This could simply
be given by the referring clinician indicating whether the
clinical diagnostic suggestion of FSHD is Deﬁnite, Proba-
ble, or Uncertain; or whether the sample is from a clinically
asymptomatic family member of a previously-diagnosed
case. Information on whether FSHD has been diagnosed
previously in another family member should in all cases
be included with the test request. From this short clinical
description of a patient, and together with an estimate of
the ‘clinical (FSHD) diagnostic likelihood’, the geneticist
can decide whether to perform additional genetic analysis,
or to forward on the sample to a more specialist lab for fur-
ther DNA tests.
In general, if a diagnosis of FSHD is expected, and
p13E-11 testing shows a typical EcoRI/BlnI shortened frag-
ment, further testing to exclude false positives would not
usually be necessary. If the clinical diagnosis is much less
certain, and not as a known family predictive situation, fur-
ther testing would often be recommended. In cases where
FSHD is much less certain (i.e. one of a number of possible
diagnoses) the absence of a typical shortened fragment
would usually be taken as excluding FSHD, without fur-
ther testing. It is in cases where the clinical diagnosis is def-
inite or probable, that further tests should be performed if
the initial EcoRI/BlnI test (or equivalent) is negative.
9. Experience and techniques of diﬀerent diagnostic labs
There were 19 laboratories who oﬀer molecular testing
for FSHD on a service basis who provided data and were
represented at the meeting. The activity for each lab varies
with ﬁve labs testing 20–50 samples per year, ﬁve testing
80–150, and eight testing 150–400 per year. The electropho-
retic method used is LGE alone in 10/19 labs (53%), PFGE
as the primary method in 6/19 (31%), and both techniques
in 3/19 (16%), including long rang PCR in one of these.
Interestingly, mosaic FSHD cases were as expected mainly
recognized by labs performing PFGE analysis on high
quality plug DNA. In routine service testing (in 16 labs)
the mean of the percentages of positive results on the index
case is: 50% (range 27–95%).
For diagnostic technique, all labs commenced with
p13E-11 DNA probe, and almost all (84%) run at least
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BlnI) on all samples. 3/19 (16%) labs perform EcoRI/BlnI
together in a single track. This latter approach may reduce
cost but will inevitably result in either false negative
(Fig. 2a) or false positive results due to the presence of
FSHD- or normal-sized hybrid repeat arrays, respectively
[27]. Data from 4 labs on these ‘complex’ cases shows that
they represent between 1% and 5% of cases.
Only 11/19 labs currently use 4qA/B telomeric polymor-
phism typing, and only in response to a request by the
referring clinician for additional testing, and on an individ-
ual case basis. The indication is usually in order to check
for a proximal (p13E-11 site) deletion in cases believed clin-
ically to have FSHD, or alternatively in prenatal diagnosis
where two shortened 4-type fragments are seen in the par-
ents, in order to check if one of these can be discounted
from being of relevance if it is of 4qB-type. No lab was
yet oﬀering the SSLP 161/163/166 polymorphism, although
some may have plans to introduce this on an individual
case basis. Similarly, no lab was yet oﬀering any methyla-
tion assay to identify cases of FSHD2, as this is not yet felt
to be suﬃciently discriminatory for service use, although it
is hoped that the technical diﬃculties will be resolved.
The main question of whether to run all available tests
(EcoRI, EcoRI/BlnI, 4qA, 4qB, SSLP) on each sample,
or whether to use a staged approach, reserving the addi-Fig. 3. Representation of typical Southern blot result of a mosaic FSHD
patient (displaying two mosaic alleles, dashed fragments), indicating that
the D4Z4 contraction occurred during somatic cell divisions in early
embryogenesis.tional tests for those where they can help answer a partic-
ular question, is ongoing. The answer to this is also not one
to be set in stone, as it may change with future advances in
diagnostic techniques.
10. Consensus genetic testing
At the end of the meeting all participants together dis-
cussed the consensus for the molecular diagnosis of
FSHD. It was concluded that for know the most suitable
method would be the conventional Southern blot based
method. For this genomic DNA is digested with EcoRI
(or EcoRI/HindIII), EcoRI/BlnI and XapI and the DNA
is separated by either LGE or PFGE. After Southern
blotting the hybridization is performed with probe
p13E-11. Because of the complex diagnostic results that
can be encountered, all participants agreed that it would
be helpful to know at the time of referral of DNA to
the lab, what the clinician’s expectation would be for
the likelihood of the patient having true FSHD. Based
on this short clinical description the geneticist can decide
whether to perform additional genetic analysis, or to for-
ward on the sample to a more specialist lab for further
DNA tests. In the ﬂowchart presented in Fig. 3, addi-
tional analysis are suggested in case the genetic analysis
based on the minimum recommended consensus experi-
ments shows an unexpected outcome based on the clinical
description.
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